Saturday 17 October 2026
Export GPCR’s income statement to Excel — free account
Structure Therapeutics Inc. Sponsored ADR
GPCR Healthcare Biotechnology
In the quarter to June 2026, EPS fell 36.4% and free cash flow fell 119.2%, each against the same quarter a year earlier.
20.95
1.24
−5.59%
Follow GPCR
Structure Therapeutics Inc. Sponsored ADR (GPCR) P/E ratio
Structure Therapeutics Inc. Sponsored ADR has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 0.0× (October 2026) — the current reading is the highest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 0.0×
Ten-year median
0.0×
Current reading's percentile
100
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| OCUL Ocular Therapeutix, Inc. compare | n/m |
| QURE uniQure N.V. compare | n/m |
| STOK Stoke Therapeutics, Inc. compare | n/m |
| ABSI Absci Corporation compare | n/m |
| MAZE Maze Therapeutics, Inc. compare | n/m |
| NTLA Intellia Therapeutics, Inc. compare | n/m |
| KRSA Korsana Biosciences, Inc. compare | n/m |
| IMCR Immunocore Holdings PLC Sponsored ADR compare | n/m |
| GPCR Structure Therapeutics Inc. Sponsored ADR | n/m |
| Biotechnology industry median | 8.5× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)